Introduction {#S1}
============

Apoptosis-associated speck-like protein containing a CARD, i.e., caspase activation and recruitment domain (ASC), also called PYCARD or TMS1 (Target of Methylation-induced Silencing-1), was originally identified as a cytosolic protein, forming large aggregates called specks in HL-60 cells after induction of apoptosis by retinoid acid and other anti-tumor drugs ([@B38]). TMS1 was independently identified during a screening for targets of methylation-associated gene silencing in human breast cancer cells ([@B7]). Structurally, ASC/TMS1 is a 22 kDa protein containing a N-terminal pyrin (PYD) domain and a C-terminal CARD domain ([@B38]; [@B37], [@B36]). ASC/TMS1 is expressed in several normal epithelial and immune cells, where it localizes in the nucleus and, upon activation, redistributes in the cytoplasm and eventually aggregates in specks ([@B38]; [@B39]).

ASC was shown to be downregulated to various extents in several human cancers when compared to the normal tissue counterpart or non-tumor adjacent tissue, suggesting a role as a tumor-suppressor ([Table 1](#T1){ref-type="table"}). This function was supported by experiments, in which ectopic ASC expression induced tumor cells to apoptosis ([@B7]; [@B42], [@B41]; [@B46]; [@B48]; [@B19]), whereas knocking down endogenous ASC inhibited tumor cell death ([@B42]; [@B45]; [@B19]). ASC was then identified as an inflammasome adaptor molecule for caspase-1 activation, pro-interleukin (IL)-1β, and pro-IL-18 cleavage and maturation ([@B36]; [@B52]), supporting a pro-inflammatory function. By promoting inflammation and specifically IL-1 release, ASC may indirectly exert pro-tumor activities by inducing chronic inflammation, angiogenesis, activation of the IL-17 pathway, myeloid-derived suppressor cell differentiation, and macrophage recruitment, invasion, and metastasis ([@B34]).

###### 

ASC/TSM1 up- and down-regulation (methylation status) and clinical correlates in human cancers.

  Tumor type                          Expression/methylation status in normal tissue                                                                           Expression/methylation status in cancer tissue                                                             Clinical correlates                                                                        Clinical outcome                                                                            References
  ----------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ------------
  Breast cancer                       Unmethylated in normal breast tissue (*n* = 3)                                                                           Methylation in 40% (11 of 27) of tumors and 44.4% (8 of 18) of paired adjacent tissues                     NE                                                                                         NE                                                                                          [@B7]
  SCLC, NSCL, breast cancer           Unmethylated in normal lung tissue (*n* = 18) and 7% (2 of 30) of normal breast tissues                                  Methylation in 41% (13 of 32) of SCLC, 40% (28 of 70) of NCSLC and 32% (20 of 63) of breast cancer         None                                                                                       NE                                                                                          [@B57]
  NSCLC                               Methylation in 12.9% (9 of 70) of normal lung tissues                                                                    Methylation in 47.1% (33 of 70) of lung tumors                                                             Methylation as an independent unfavorable prognostic factor                                Patients with unmethylated tumors had better survival                                       [@B61]
  Lung cancer                         Expressed in normal tissue (*n* = 6) and pre-cancerous lesions (*n* = 10) Methylation in 1 of 23 pre-cancerous lesions   Reduced expression in 75% (30 of 40) of tumors Methylation in 27% (41 of 152) of tumors                    Methylation correlates with lymphatic invasion, lymph node metastases and advanced stage   Methylation in sputum DNA predicts prognosis in patients resected for early stage disease   [@B31]
  Colorectal cancer                   Methylation in 12.5% (2 of 16) normal tissue                                                                             Methylation in 25% (4 of 16) of tumors                                                                     Methylation associates with lack of nodal metastases                                       NE                                                                                          [@B41]
  Colorectal cancer                   Methylation in 20% (2 of 10) of adjacent normal tissues                                                                  Partial methylation in 60% (6 of 10) of tumors                                                             NE                                                                                         NE                                                                                          [@B60]
  Colorectal cancer                   Unmethylated in normal tissue (*n* = 11) and adenomas (*n* = 30)                                                         Methylation in 17% (20 of 115) of tumors                                                                   Methylation more common in right-sided tumors and in late stages                           NE                                                                                          [@B49]
  Melanoma                            Highly expressed in melanocytic nevi (*n* = 18)                                                                          Absent or reduced in 62.5% (20 of 32) of melanomas                                                         NE                                                                                         NE                                                                                          [@B15]
  Melanoma                            Highly expressed in normal melanocytes                                                                                   Downregulated in primary (*n* = 6) and in metastatic lesions (*n* = 6)                                     NE                                                                                         NE                                                                                          [@B30]
  Ovarian cancer                      Unmethylated in normal ovary tissue (*n* = 4)                                                                            Methylation in 19% (15 of 80) of tumors                                                                    Methylation correlates with clear cell-type tumors                                         No correlation with prognosis                                                               [@B55]
  Ovarian cancer                      NE                                                                                                                       Methylation in 40% (8 of 20) of tumors                                                                     NE                                                                                         NE                                                                                          [@B1]
  Glioblastoma                        Expressed and unmethylated in normal brain (astrocytes)                                                                  Methylation in 43% (10 of 23) of tumors                                                                    None                                                                                       Increased survival in patients with unmethylated tumors                                     [@B54]
  Glioblastoma                        NE                                                                                                                       Methylation in 21.05% (12 of 57) of tumors                                                                 Methylation increased (4 of 7) in long-term survivors                                      Increased survival in patients with methylated tumors                                       [@B35]
  Neuroblastoma                       NE                                                                                                                       Methylation in 31% (45 of 145) of tumors                                                                   Methylation correlates with advanced disease                                               Methylation associates with reduced survival                                                [@B2]
  Medulloblastoma                     NE                                                                                                                       Expression in 60% (9 of 11) of tumor samples                                                               NE                                                                                         NE                                                                                          [@B25]
  Prostate cancer                     Unmethylated in normal tissues (*n* = 14) Methylation in 28% (11 of 40) of adjacent tissue                               Methylation in 65% (38 of 58) of tumors and 64% (7 of 11) of high-grade intraepithelial neoplasia          Methylation in adjacent tissue correlates with biochemical recurrence                      None                                                                                        [@B6]
  Prostate cancer                     NE                                                                                                                       Methylation in 63.6% (42 of 66) of tumors and 35% (12 of 34) of prostate hyperplasia                       Methylation more prevalent in the white race                                               NE                                                                                          [@B9]
  Gastric cancer                      NE                                                                                                                       Methylation in 32.1% (20 of 80) of tumors                                                                  None                                                                                       Reduced survival for patients with methylation                                              [@B23]
  Gastric cancer                      Expression higher than in tumor tissue and unmethylated (*n* = 40)                                                       Methylation in 34% (68 of 200) of tumors                                                                   Methylation correlates with tumor size and lymph node metastases                           Reduced survival for patients with methylation                                              [@B59]
  Gastric cancer                      Expression lower than in tumors in two patient cohorts (*n* = 10 and *n* = 18)                                           Expression higher than in non-tumor adjacent tissues in the same patient cohorts                           Correlation between ASC and IL18 mRNA levels                                               NE                                                                                          [@B11]
  Cervical cancer                     Methylation in 2.5% (2 of 80) of non-tumor adjacent tissue                                                               Methylation in 6.2% (5 of 80) of tumors                                                                    None                                                                                       NE                                                                                          [@B27]
  Renal cell carcinoma                Highly expressed in adjacent non-cancerous tissues (*n* = 67) Methylation in 12% of normal tissue                        Downregulation in tumor compared to normal tissues (*n* = 67) Methylation in 41.1% (83 of 202) of tumors   Methylation correlates with higher nuclear grade                                           NE                                                                                          [@B29]
  Oral squamous cell carcinoma        Highly expressed in normal oral mucosa (*n* = 6)                                                                         Downregulation in tumors as a function of differentiation grade                                            Correlation with clinical features                                                         Better survival in patients with higher ASC score (% of positive cells)                     [@B50]
  Oral squamous cell carcinoma        Downregulated in normal tissue compared to tumors (*n* = 20)                                                             Upregulated in tumors compared to normal mucosa (*n* = 111)                                                ASC increased expression as an independent predictor of survival                           ASC expression correlated with reduced survival                                             [@B58]
  Cutaneous squamous cell carcinoma   Expressed in normal tissue                                                                                               Loss of expression in de-differentiated G3 tumors                                                          None                                                                                       NE                                                                                          [@B40]
  Pancreatic ductal adeno-carcinoma   Weak staining in adjacent non-tumor tissue (*n* = 41)                                                                    ASC expression in all tumor samples; i.e., 90% (37 of 41) of tumor cells and 100% of TAMs (*n* = 41)       NE                                                                                         Increased survival in patients with ASC mRNA expression inferior to the median values       [@B4]

NE, not evaluated.

In this review, we summarize and discuss data from the literature describing both ASC functions (pro-apoptotic and pro-inflammatory), their implication in anti-tumor or pro-tumor activity, the correlation between ASC expression/upregulation or down-regulation by aberrant methylation in tumor and clinical correlates, and survival in neoplastic patients.

ASC/TMS1 as Tumor Suppressor {#S2}
============================

Apoptosis is a regulated cell death process, which results in the clearance of dying cells with minimal damage to surrounding tissues ([@B14]; [@B51]). Once cell damage is detected, a series of cysteine-aspartic proteases called caspases are activated. These include initiator caspases (caspase-8 and -9), which in turn activate executioner caspases (e.g., caspase-3), initiating a cascade of events resulting in DNA fragmentation, destruction of nuclear proteins and cytoskeleton with chromatin and cytoskeleton condensation, expression of ligands for phagocytic cells, and the formation of apoptotic bodies ([Figure 1A](#F1){ref-type="fig"}). Apoptotic bodies are removed by macrophages before their fragmentation, reducing the risk of collateral damage to adjacent cells.

![Dual role of ASC/TMS1 in cancer. **(A)** Pro-apoptotic function. In normal epithelial cells differentiation and stress/damage cell signals induce the onco-suppressor p53 to activate transcription of several genes, among these ASC. Activated ASC binds to Bax and the ASC-Bax complex translocates to mitochondria mediating Citochrome C (Cit C) release. Cit C activates the initiator caspases-8 or -9, which in turn activate caspase-3 and the apoptotic cascade. At difference with normal epithelial cells, in cancer cell methylation (Meth) of the promoter region of ASC induces gene silencing and inhibits apoptosis, thus contributing to cell survival and tumor development ([@B16]). **(B)** Pro-inflammatory function in cancer cells. In cancer cells and myeloid cells (such as TAMs), recognition of pathogen- or damage-associated molecular patterns (PAMPs, DAMPs) induces the assembly/polymerization of the inflammasome molecular complex, which in cancer cells is otherwise often constitutively activated as a result of genetic lesions ([@B26]; [@B20]; [@B21]; [@B22]). The inflammasome is composed by a multimerized module formed by a sensor Nod Leucine-Rich Repeat-containing receptor, such as NLRP3, bound to the pyrin domain of the adaptor ASC, which in turn is bound, through its CARD domain, to pro-caspase-1. The multimerized complex forms a speck that induces caspase-1 activation. Caspase-1 can then catalyze the proteolytic cleavage and activation of IL-1β and IL-18. Sensing of PAMPS or DAMPS also induces activation of NF-κB, which translocates to the nucleus and activates transcription of pro-IL-1β and pro-IL-18. ASC specks and inflammatory cytokines (IL-1β and IL-18) are released from cancer cells, through mechanisms not completely elucidated (?), and captured by TAMs contributing to massive IL-1β release with auto-activation of cancer cells, as well as triggering of other immune or stromal cell components in the tumor microenvironment. IL-18 can contribute to cancer cell proliferation by inhibiting caspase-8 mediated apoptosis.](fcell-08-00040-g001){#F1}

Apoptosis is initiated by intracellular or extracellular microenvironmental perturbations that trigger the intrinsic (mitochondrial outer membrane permeabilization-mediated) or the extrinsic (death receptor-mediated) pathways, respectively. Failure of apoptosis and consequent accumulation of damaged cells is associated with tumor formation ([@B14]; [@B51]). Indeed, tumor cells develop strategies to limit or circumvent apoptosis, such losing the p53 tumor suppressor function, increasing expression of anti-apoptotic regulators (the Bcl-2 protein family) or survival signals (Igf1/2), downregulating pro-apoptotic factors (Bax), or avoiding the extrinsic ligand-induced death pathway ([@B16]).

As reported above, ASC was found to be silenced by DNA methylation in cancer cells from different tumors, indicating a role as an anti-tumor pro-apoptotic factor ([Table 1](#T1){ref-type="table"}).

A mechanism of the caspase-9-dependent pro-apoptotic function for ASC/TMS1 was first described in [@B39], where apoptosis was accompanied by the redistribution of ASC/TMS1 from the cytoplasm to perinuclear spherical structures similar to the large aggregates (i.e., specks) described in [@B38]. Pro-apoptotic activity as well as spherical structure formation were dependent on the CARD portion of molecule. Whereas the apoptotic activity of ASC was blocked by caspase inhibition, the formation of the spherical structures was not, suggesting that ASC redistribution precedes caspase activation.

[@B28] investigated at the molecular level the regulation of TMS1 silencing by methylation in human breast cancer cells. The authors characterized the ASC/TMS1 locus with regard to the methylation status by comparing the fine mapping of methylation in normal mammary epithelial cells, breast cancer cell lines (either positive or negative for TMS1 expression), and primary breast tumors. The region surrounding the transcription start site was found to be crucial for TMS1 expression. In primary tumors, the methylation-associated silencing of TMS1 was usually present in a subset of tumor cells, while TMS1 negative cell lines showed a nearly complete methylation at each CpG islands in all alleles. The authors suggested a model, in which dense methylation and gene silencing are events tightly combined and involving local remodeling of CpG island chromatin ([@B28]). A similar association between ASC silencing and methylation status was reported in several other neoplastic diseases ([Table 1](#T1){ref-type="table"}).

The mechanisms of ASC-mediated apoptosis were studied using *in vitro* cell line models ([@B42]). ASC was shown to induce apoptosis in a p53-dependent manner. In response to genotoxic agents, p53 induced ASC expression by binding to its promoter and activating its transcription. In this model, Bax, a pro-apoptotic protein that causes p53-mediated mitochondrial dysfunction, interacted with ASC through its Pyrin domain in the cytoplasm. The Bax-ASC complex then translocated to the mitochondria and induced the release of cytochrome C, which in turn triggered apoptosis through the activation of caspase-9, -2, and -3. Collectively, this study demonstrated that ASC acts as an adaptor molecule for Bax, and regulates a p53-Bax mitochondrial pathway of apoptosis.

The effects of ASC expression on p53-mediated chemosensitivity were subsequently evaluated in colon cancer ([@B41]). ASC overexpression in p53-expressing tumor cells promoted cell death and increased chemosensitivity, suggesting that methylation-induced silencing of ASC might cause resistance to p53 mediated chemosensitivity, and that restoration of ASC expression should increase chemotherapy efficacy.

A mechanism of resistance to anoikis mediated by TMS1/ASC has been reported in breast cancer early carcinogenesis ([@B45]). Anoikis is a form of programed cell death provoked in epithelial cells by detachment from the extracellular matrix. Resistance to anoikis is acquired by epithelial cells during carcinogenesis. TMS1/ASC expression was reduced in a subset of *in situ* lesions where the epithelial cells had filled the breast duct, and in 16% of the invasive ductal carcinomas. These data are suggestive of a possible role of TMS1/ASC in the transition from *in situ* to invasive lesions. *In vitro* forcing suspension of breast epithelial cells resulted in TMS1/ASC expression, which preceded that of the proapoptotic protein Bim (known to be upregulated during anoikis). TMS1/ASC knockdown inhibited Bim induction, procaspase-8 cleavage, and led to persistence of MAPK/ERK survival pathways, suggesting that TMS1/ASC silencing contributes to the resistance to anoikis.

One study ([@B29]) evaluated epigenetic alteration and the biological function of ASC/TMS1 in renal cell carcinoma. ASC/TMS1 was downregulated in tumor cell lines and tumor compared to normal tissue samples. Downregulation of ASC/TMS1 correlated with its promoter methylation and could be restored by treatment with demethylating agents. ASC/TMS1 re-expression inhibited tumor cells viability and colony formation, arrested cell cycle, induced apoptosis, suppressed cell invasion and repressed tumorigenicity in immunodeficient mice. All these functions were partially regulated by activation of the p53 signaling.

More recently, the effects of ASC on cell viability were studied using different cell density conditions ([@B24]). The authors found that at high-density, cell viability was suppressed by ASC-dependent apoptosis induced by cleavage of caspase-9, and by suppression of the NF-κB related X-linked inhibitor-of-apoptosis protein expression. Caspase-9 cleavage was partially dependent on enhanced gap junction formation.

An anti-tumor but not pro-apoptotic mechanism for ASC, which involves caspase-8, was identified in [@B43]. The authors found that ASC ablation in murine tumor cell lines *in vitro* enhanced cellular motility and invadopodia formation through cytoskeletal reorganization, as well as Src accessibility to caspase-8 for ensuing phosphorylation (*p*-caspase-8 is pro-metastatic) and cellular migration. Indeed, *in vivo* this effect was associated to reduced metastatic potential.

In summary, a role for ASC/TMS1 as a pro-apoptotic tumor suppressor factor has been assessed in different tumors where it was found to be downregulated in variable percentages in primary tumors. Mechanistic studies clarified that lack of ASC/TMS1 protein expression was associated at the molecular level with hypermethylation of its promoter region. *In vitro* ASC/TMS1 expression could be at least partially restored upon treatment with demethylating agents, and forced expression of the ASC/TIMS1 gene by transfection in negative tumor cell lines endowed them with apoptotic capability. Future studies are needed to determine what stimulate ASC to induce apoptosis in cancer, as upregulation of ASC *per se* is possibly not sufficient.

ASC as Inflammasome Adaptor Molecule {#S3}
====================================

Inflammation, which is an enabling hallmark of cancer ([@B16]), contributes to tumor development/progression through several mechanisms. For example, through providing soluble molecules to the tumor microenvironment (including growth, survival, and proangiogenic factors); through enzymes, which modify the extracellular matrix to favor angiogenesis, invasion and metastasis; and through signals to activate epithelial to mesenchymal transition ([@B33]; [@B16]).

Inflammatory responses originate in response to microbial and danger signals, through the activation of large cytoplasmic protein complexes, termed inflammasomes, which are essential for the production of active IL-1β and IL-18 cytokines ([@B36]). ASC plays a central role during inflammasome activation by interacting via its PYD domain with pattern recognition receptors (e.g., NLRP3), and via its CARD domain with pro-caspase-1, leading to caspase-1-activation and proIL-1β and proIL-18 maturation ([@B36]; [@B52]).

The role of inflammasomes in cancer has been recently discussed elsewhere ([@B26]; [@B20]; [@B21]; [@B22]; [@B56]). We refer readers interested in comprehensive summaries of the field to those reviews.

We focus here on ASC for which a role in tumor development/progression, as an inflammasome adaptor molecule, occurring through different indirect mechanisms, has been reported ([Figure 1B](#F1){ref-type="fig"}).

In a mouse model of epithelial skin carcinogenesis, the function of ASC in tumor initiation or suppression was studied using conditional ASC knockout mice ([@B12]). IL-1 receptor- or caspase-1-deficient mice showed reduced cancer incidence and tumor numbers compared to wild-type controls. However, ASC-deficient mice were not protected. To differentiate putative tumor-suppressive from tumor-promoting functions, mice deficient in ASC in keratinocytes or in myeloid cells were generated. While mice deficient in ASC in keratinocytes developed more tumors than controls, those deficient in myeloid cells were protected. ASC-deficient keratinocytes enhanced their proliferation both *in vitro* and *in vivo*, possibly through p53 activation. ASC deletion in myeloid cells was associated with significantly reduced IL-1β in the tumor. According to the dual role of ASC in skin carcinogenesis, ASC protein expression was lost in human cutaneous squamous cell carcinoma, but not in inflammation-induced epidermal hyperplasia, such as psoriatic skin lesions ([@B12]; [@B40]). Collectively, these studies suggested that ASC in different tumor components (i.e., epithelium vs stroma) may influence tumor growth in opposite directions.

The role of ASC in melanogenesis was studied using primary and metastatic melanoma cell lines ([@B30]). The results showed that ASC has tumor stage-dependent dual roles in tumorigenesis (i.e., suppresses tumor growth in primary melanoma while it promotes tumor growth of metastatic melanoma) by different regulations of NF-κB activity. In primary melanoma ASC inhibited phosphorylation of IκB Kinase and decreased NF-κB activity with low pro-IL-1β synthesis and release. In metastatic melanoma, auto-active IL-1 receptor and other signaling pathways resulted in reduced NF-κB inhibition by ASC in the presence of sustained auto-active inflammasome, leading to spontaneous IL-1β synthesis and release ([@B30]). These data further clarify the mechanisms of previous results, in which constitutively assembled and activated NLRP3 inflammasome resulted in spontaneous IL-1β secretion in metastatic melanoma ([@B44]). Interestingly, ASC was also reported to differentially regulate NF-κB activity toward either enhancement or inhibition, depending on the ratio of its levels to other ASC-binding proteins (e.g., Cryopyrin/PYPAF-1, Pyrin, PYPAF-7, and caspase-8 for enhancement, and IKK complex components IKKα, IKKβ and IKKγ for inhibition, respectively) ([@B32]; [@B53]; [@B17]).

A pro-tumorigenic function for ASC, through its effector cytokine IL-18, was recently described in gastric cancer ([@B11]), where ASC was significantly upregulated in the tumor compared to normal gastric tissue. Mechanistic studies were performed on spontaneous mouse models of gastric cancer. In these mice, ablation of ASC was associated with reduced NF-κB, caspase-1 activation, and enhanced numbers of caspase-3 and -8 positive tumor cells, suggesting a tumor-promoting function for ASC by limiting apoptosis in the gastric epithelium, independently of its pro-inflammatory effects. Similarly, ASC deletion or IL-18 blockade in tumor cells increased apoptosis ([Figure 1](#F1){ref-type="fig"}), and in tumor samples elevated levels of IL-18 and ASC mRNA showed positive correlation, supporting a role for IL-18 in protecting tumor cells from apoptosis. Collectively, the study suggests the existence of a novel ASC/IL-18/NF-κB signaling axis that augments tumor cell survival in gastric cancer.

A novel role for extracellular ASC released by tumor cells in pancreatic cancer was recently reported ([@B4]). In this study, IL-1α and IL-1β from tumor cells and tumor associated macrophages (TAMs) were key to inducing cancer-associated fibroblasts (CAFs) to secrete the thymic stromal lymphopoietin (TSLP), which in turn drives predominant tumor-promoting Th2 cells, through the activation of resident dendritic cells with Th2 polarizing capability ([@B10]; [@B47]). It has been shown that ASC assemble and form specks that are released by dying cells, and phagocytosis of ASC specks by macrophages leads to IL-1 maturation through caspase-1 activation ([@B3]; [@B13]), suggesting that extracellular ASC specks serve as danger signals ([Figure 1B](#F1){ref-type="fig"}). Indeed, *in vitro* studies showed that ASC released by tumor cells induced IL-1β release by macrophages, and CAFs, activated with the supernatant of ASC positive tumor cell-conditioned macrophages, secreted TSLP. Collectively, ASC in pancreatic cancer exert an indirect role in driving predominant Th2-type inflammation, through a complex cross-talk between tumor cells and its microenvironment. Importantly, in a murine model, in which ASC-deficient mice were orthotopically implanted with KPC-derived tumor cells \[i.e., tumor cells derived from a spontaneous mouse model of pancreatic cancer ([@B18])\], tumors grew at lower rate in ASC-deleted compared to wild-type mice ([@B8]). Collectively, these studies indicate a tumor-promoting function for ASC in pancreatic cancer.

ASC Expression/Aberrant Methylation and Clinical Outcome {#S4}
========================================================

The levels of ASC mRNA and protein expression have been investigated in several neoplastic diseases using reverse transcription polymerase chain reaction. This was in order to specifically address the presence of a hypermethylated status, and, by immunohistochemistry, to morphologically distinguish ASC expression in tumor cells and myeloid cells within the tumor microenvironment. In the majority of studies, the levels of ASC expression in the normal tissue counterpart and/or in non-tumor adjacent tissues were evaluated for comparison ([Table 1](#T1){ref-type="table"}).

In this section, we report and discuss those studies, in which the relevance of ASC expression and/or hypermethylation in relation to clinical features and/or survival have been addressed.

ASC expression and methylation status in lung cancer \[i.e., small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)\], were evaluated in three studies ([@B57]; [@B31]; [@B61]). In non-malignant tissue, ASC was expressed, whereas reduced ASC expression was found in 75% of primary lung carcinoma ([@B31]) with aberrant methylation among 27--47% of tumor samples, predominantly in NSCLC ([@B57]; [@B31]; [@B61]). [@B57] did not find any correlation between the methylation status and a specific NSCLC histologic subtype, tumor stage, or lymph-node metastases, whereas in the other two studies ([@B31]; [@B61]), methylation was identified as an independent unfavorable prognostic factor in multivariate analysis ([@B61]), and correlated with lymphatic invasion, lymph-node metastases, and advanced disease ([@B31]), respectively. Patients with unmethylated tumors had increased survival ([@B61]), and ASC methylation in sputum DNA predicted prognosis in patients resected for early stage disease ([@B31]). Collectively, it is agreed that in lung cancer, ASC aberrant methylation associates with negative clinical outcome.

Aberrant methylation was found in 31% of neuroblastomas ([@B2]). A higher frequency of methylated tumors were found at more advanced-stage disease, and a higher frequency of unmethylated tumors were found in patients with spontaneous remission. Patients with methylated tumors also had a shorter survival compared with those with unmethylated tumors ([@B2]), suggesting a clinically relevant pro-apoptotic role for ASC in neuroblastoma.

Two studies ([@B23]; [@B59]) evaluated ASC expression and methylation status in gastric cancer, with very similar findings. The methylation rate in tumors was 32--34%, and ASC expression was reduced in tumors compared to normal gastric tissue. The methylation status in the tumor correlated with the primary tumor size and lymph node metastases in multivariate analyses ([@B59]); patients with methylated tumor exhibited shorter survival ([@B23]; [@B59]). Collectively, reduced ASC expression in gastric cancer seems to correlate with worse clinical outcome.

In two studies ([@B1]; [@B55]), ASC aberrant methylation was found in 19--40% of ovarian cancers, respectively. [@B55] reported an association between ASC methylation and clear cell-type tumors, whereas they did not find any correlation with prognosis. Collectively, alteration in ASC expression does not seem to have a clear clinical impact in ovarian cancer.

High frequency of hypermethylation (63--65%) was found in primary prostate cancer ([@B6]; [@B9]). Of note, high frequency of methylation (35%) was also detected in benign prostate hyperplasia ([@B9]) and in 64% of high-grade intraepithelial neoplasia ([@B6]). As a clinical correlate, a high rate of ASC methylation in non-tumor adjacent tissue was found in patients with biochemical recurrence. However, no correlation with survival was observed ([@B6]), not supporting clinical relevance for ASC expression in prostate cancer.

In pancreatic cancer ASC expression in the tumor, evaluated by immunohistochemistry, was upregulated in over 90% of tumor samples compared with surrounding tissue ([@B4]). Analysis in ASC expression distribution within the tumor showed that, in addition to the expression in tumor cells, ASC was also highly expressed in TAMs in all samples. Patients with ASC mRNA expression inferior to the median value had a significantly increased survival ([@B4]), suggesting that ASC expression in pancreatic cancer correlates with an unfavorable clinical outcome.

Lastly, conflicting results were obtained in glioblastoma and oral squamous cell carcinoma. Aberrant methylation was present in 43% of glioblastomas, whereas ASC was unmethylated and expressed in normal brains ([@B54]). No correlation was found with age, gender or treatment, although a trend in increased survival for patients with unmethylated tumors was observed ([@B54]). In another study ([@B35]), hypermethylation was present in 21% of glioblastomas and, at variance with the previous report ([@B54]), methylation was significantly more frequent in long-term survivors. In agreement with this finding, a tendency for better outcome in patients with methylated ASC was also observed ([@B35]). Collectively, the two studies yielded opposing results in terms of clinical relevance, possibly because of the limited number of cases studied. Further investigations are needed to better define the contribution of ASC expression in glioblastoma.

Concerning oral squamous cell carcinoma, one study ([@B50]) found ASC highly expressed in normal oral mucosa, whereas expression was reduced in tumors as a function of the differentiation grade (well, moderately and poorly differentiated). ASC expression correlated with tumor site, T-classification, clinical stage, mode of invasion, histopathological differentiation, and lymphocytic infiltration. Survival rate was significantly higher in patients with a higher score (increasing with the percentage of positive cells) ([@B50]). On the contrary, in another study ([@B58]), ASC expression was higher in the tumor compared to the adjacent normal mucosa, and its expression correlated with tumor stage, node involvement, extracellular spread, perineural invasion, and tumor depth. Patients with higher ASC expression showed reduced survival and in multivariate analysis ASC upregulation was an independent predictor of survival ([@B58]). Possible explanations for these contradictory results might be the different scoring methods for immunohistochemistry. Due to this important discrepancy in survival, the clinical relevance of ASC expression in oral squamous cell carcinoma cannot be definitively ruled out.

Concluding Remarks {#S5}
==================

Through diverse activation stimuli and not completely understood receptor-ligand interactions, ASC can start two different intracellular signaling pathways (i.e., apoptosis and inflammasome maturation) ([Figure 1](#F1){ref-type="fig"}).

In tumors, ASC can be either downregulated, mostly by aberrant methylation, or upregulated in tumor cells and overexpressed in the myeloid compartment (mostly TAMs) within the tumor microenvironment.

ASC can be expressed in normal epithelial cells or non-tumor adjacent tissues, and when it is downregulated in tumor cells, the prevalent role is usually anti-tumor by activation of apoptotic pathways. On the contrary, when tumor cells have upregulated ASC expression compared with that of the normal tissue counterpart, ASC is more commonly associated with tumor-promoting functions, either by inducing the release of pro-inflammatory cytokines, or by acting as danger signals when released in the extracellular space as specks, thus perpetuating inflammation. Indeed, ASC expression in myeloid cells is associated with tumor-promoting inflammation.

ASC can be targeted by therapeutic strategies, which are already in the clinical practice or under development, aimed to either increase its expression (i.e., demethylating agents) or interfere with inflammasome components ([@B5]). However, due to the opposite anti-tumor or pro-tumor ASC functions, future therapeutic applications for ASC targeting should well monitor tissue- and cell type-specific tumor contexts.
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